Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis — Famuspa  

Fatigue Clinical Trial

Official title: Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis

Status Not yet recruiting

Clinical Trial Summary

Axial spondyloarthropathy (SpA) is the most common inflammatory rheumatism (1% of the general population) with important medico-economic consequences.

Fatigue is a major feature of SA. It can be defined as a feeling of reduced muscle capacity, lack of energy and exhaustion. The fatigue reaches an abnormally high level (fatigue severity score (FSS) ≥4, called severe fatigue in this protocol) in more than two thirds of patients with SA.

Skeletal muscle repercussions are present during SA. It is characterized by a decrease in exercise capacity independently of pain and ankylosis but is associated with a decrease in strength and muscle mass, the importance of which varies from one study to another.

The link between fatigue (subjective sensation) and the skeletal muscular impact (objective) of SA has never been studied.

Clinical Trial Description

This work will:

1. Study for the first time the implication of the objective skeletal muscular impact in fatigue during SA.

2. Better characterize the skeletal muscle impact of SA;

3. Characterize the evolution of the fatigue and the muscular impact under targeted therapy ;

Related Conditions & MeSH terms

• Axial Spondyloarthritis
• Exercise Capacity
• Fatigue
• Spondylarthritis
• Spondylitis
• Spondyloarthritis, Axial

• NCT number: NCT03940911
• Study type: Interventional
• Source: University Hospital, Strasbourg, France
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 17, 2024
• Completion date: October 16, 2024